21 March 2023
Benchmark Holdings plc
("Benchmark" or the "Company")
Share Premium Reduction
21 March 2023
The Company announces that the cancellation of its share premium account (the "Capital Reduction"), which was approved by shareholders on 16 February 2023, is now effective. This follows the confirmation of the Capital Reduction by the High Court of England and Wales on 14 March 2023 and the registration of the Court order with the Registrar of Companies on 20 March 2023.
The Capital Reduction creates additional distributable reserves to the value of £394,235,072. The Company confirms that, following the Capital Reduction, the issued share capital of the Company remains at 739,277,469 ordinary shares of £0.001 each. The total number of voting rights in the Company also remains at 739,277,469.
Enquiries
For further information, please contact: |
|
Benchmark Holdings plc |
Tel: 0114 240 9939 |
Ivonne Cantu, Investor Relations |
|
Numis (Broker and NOMAD) |
Tel: 020 7260 1000 |
James Black, Freddie Barnfield, Duncan Monteith |
|
MHP |
Tel: 020 3128 8793 |
Katie Hunt, Reg Hoare, Veronica Farah |
|
About Benchmark
Benchmark is a market leading aquaculture biotechnology company. Benchmark's mission is to drive sustainability in aquaculture by delivering mission-critical products and solutions in genetics, advanced nutrition and health which improve yield, growth and animal health and welfare. Through a global footprint in 26 countries and a broad portfolio of products and solutions, Benchmark addresses the major aquaculture species - salmon, shrimp, sea bass and bream, and tilapia, in all the aquaculture regions around the world.
Find out more at www.benchmarkplc.com.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy. ENDMSCUAOBROUUOUAR
==